Targeted therapy tested in dermatomyositis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Targeted therapy tested in dermatomyositis

Researchers found higher composite improvement scores and greater glucocorticoid tapering with the 30‐mg dose, though serious infections were more frequent.

  • By

  • Kathryn Wighton

  • August 20, 2026

  • 4 min

Share

  • 1

    Brepocitinib 30 mg daily significantly improved Total Improvement Scores in dermatomyositis patients compared to placebo in a phase 3 trial.

  • 2

    The VALOR trial involved 241 adults with active muscle and skin disease, randomized to receive brepocitinib or placebo for 52 weeks.

  • 3

    At week 52, 68% of patients on brepocitinib 30 mg achieved moderate improvement, compared to 44% on placebo.

  • 4

    Serious infections were more common in the brepocitinib 30 mg group, occurring in 10% of patients versus 1% in the placebo group.

  • 5

    The study was funded by Priovant Therapeutics, and no mortality events or opportunistic infections were reported during the trial.

Original Source(s)

Targeted therapy tested in dermatomyositis

  • by Kathryn Wighton

  • August 20, 2026

Related Content

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Vitiligo Gets Long-Missing Definitions for Severity and Relapse

A new international consensus framework standardizes how disease severity and relapse are defined, addressing inconsistencies that have complicated clinical trials and treatment decisions.

What Parents Need to Know About Moles in Children